H L McLeod|M V Relling - JoVE Visualize

Showing results (111-120 of 281) with videos related to

Pageof 29

Sort By:

Clinical Pharmacology and Therapeutics|September 11, 2009

Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemiaJ C Panetta, A Gajjar, N Hijiya, et al.

The Pharmacogenomics Journal|November 10, 2004

Interethnic variability of ERCC2 polymorphismsC R King, J Yu, R R Freimuth, et al.

The Journal of Pharmacology and Experimental Therapeutics|July 1, 1994

Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white AmericansH L McLeod, L Fang, X Luo, et al.

Genomics|June 22, 1999

Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populationsS Marsh, E S Collie-Duguid, T Li, et al.

European Journal of Cancer (Oxford, England : 1990)|August 1, 1996

Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials GroupH L McLeod, M A Graham, S Aamdal, et al.

Human Mutation|November 3, 2000

Pharmacogenetics of catechol-O-methyltransferase: frequency of low activity allele in a Ghanaian populationM M Ameyaw, A C Syvänen, I Ulmanen, et al.

The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001

Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?B Rochat, J M Morsman, G I Murray, et al.

Experimental Eye Research|September 1, 1990

Modelling cortical cataractogenesis. XI. Vitamin C reduces gamma-crystallin leakage from lenses in diabetic ratsH A Linklater, T Dzialoszynski, H L McLeod, et al.

Pharmaceutical Research|September 16, 2000

Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoproteinC Brimer, J T Dalton, Z Zhu, et al.

Mutation Research|November 7, 1998

The frequency of illegitimate V(D)J recombinase-mediated mutations in children treated with etoposide-containing antileukemic therapyJ C Fuscoe, G W Knapp, N M Hanley, et al.

Pageof 29

Showing results (111-120 of 281) with videos related to

Sort By:

Pageof 29

Clinical Pharmacology and Therapeutics|September 11, 2009

Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemiaJ C Panetta, A Gajjar, N Hijiya, et al.

The Pharmacogenomics Journal|November 10, 2004

Interethnic variability of ERCC2 polymorphismsC R King, J Yu, R R Freimuth, et al.

The Journal of Pharmacology and Experimental Therapeutics|July 1, 1994

Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white AmericansH L McLeod, L Fang, X Luo, et al.

Genomics|June 22, 1999

Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populationsS Marsh, E S Collie-Duguid, T Li, et al.

European Journal of Cancer (Oxford, England : 1990)|August 1, 1996

Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials GroupH L McLeod, M A Graham, S Aamdal, et al.

Human Mutation|November 3, 2000

Pharmacogenetics of catechol-O-methyltransferase: frequency of low activity allele in a Ghanaian populationM M Ameyaw, A C Syvänen, I Ulmanen, et al.

The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001

Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?B Rochat, J M Morsman, G I Murray, et al.

Experimental Eye Research|September 1, 1990

Modelling cortical cataractogenesis. XI. Vitamin C reduces gamma-crystallin leakage from lenses in diabetic ratsH A Linklater, T Dzialoszynski, H L McLeod, et al.

Pharmaceutical Research|September 16, 2000

Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoproteinC Brimer, J T Dalton, Z Zhu, et al.

Mutation Research|November 7, 1998

The frequency of illegitimate V(D)J recombinase-mediated mutations in children treated with etoposide-containing antileukemic therapyJ C Fuscoe, G W Knapp, N M Hanley, et al.

Pageof 29